How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis
Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.
Pharma & Biotech
Medical Devices & Diagnostics
Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?
New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.